American College of Cardiology

News Releases - Monday, March 31

Contact:
Amy Murphy, amurphy@acc.org

ACC.08

1 p.m.

Effect of the Direct Renin Inhibitor Aliskiren, Either Alone or in Combination With Losartan, Compared to Losartan, on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy: The Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial

Echocardiographic Tissue Doppler Imaging Is a Powerful Independent Prognosticator of Overall Mortality in the General Population. Results From the Fourth Copenhagen City Heart Study (2002-2007)

Efficacy and Safety of the Selective Adenosine A2A Receptor Agonist Binodenoson for Pharmacologic Stress: Results of a Phase 3, Randomized, Double-Blind, Risk-Stratified, Active-Controlled, Crossover Trial

Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Atorvastatin on Inflammatory Activity in Human Carotid Atherosclerotic Plaques: A Prospective Randomised Double-Blind Trial With USPIO-Enhanced High Resolution Magnetic Resonance maging

Safety and Efficacy of Commercially Available Ultrasound Contrast Agents in a Clinical Setting

International PRospective Multicenter Study On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice

Effects of a Selective Inhibitor of Secretory Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways

10 a.m.

Results of the ONTARGET Study Comparing Ramipril With Telmisartan, and Its Combination in High-Risk Individuals Without Heart Failure

Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living with Systolic Hypertension, the Early Termination of the ACCOMPLISH Trial for Efficacy

The Hypertension in the Very Elderly Trial (HYVET): Main Results

Effect of Rosuvastatin Therapy on Coronary Artery Stenoses in the ASTEROID Trial

Effect of Pioglitazone Versus Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes (PERISCOPE)

Cardiovascular Risk of Celecoxib in Six Randomized Placebo-Controlled Trials: The Cross-Trials Safety Assessment Pooled Analysis